“We hope to maximally suppress HIV and potentially contribute to a cure for AIDS.” Dr. Rodney Ho
Targeted Long Acting Therapy intended to clear virus in tissues
We are the Targeted Long-acting Combination Anti-Retroviral Therapy (TLC-ART) program, located within the Department of Pharmaceutics at the University of Washington. We are scientists and physicians working toward developing a long acting and effective treatment to improve patient compliance and therapeutic outcomes in the treatment of HIV. Our hope is to maximally suppress HIV and potentially contribute to a cure for AIDS.
Our researchers were the first to document pharmacological drug deficiency with HIV oral treatment. This has been linked to residual HIV in tissues. The TLC-ART program, with its 11 projects, intends to overcome pharmacological drug deficiency by developing a novel formulation of a combination of antiretroviral agents. TLC-ART is a publicly funded, National Institutes of Health (NIH) supported program with contributions from multiple institutions.